| アブストラクト | (1) The initial clinical assessment files on hepatitis B vaccines showed no risk of severe systemic adverse effects. (2) Pharmacovigilance data obtained in several countries show that hepatitis B vaccination carries a risk of very rare anaphylactic reactions. (3) Anecdotal observations have raised the worrying possibility that neurological and "autoimmune" conditions may be caused or worsened by hepatitis B vaccination in some patients. Current epidemiological data do not support this possibility, but do not formally exclude it. (4) The risk-benefit ratio of hepatitis B vaccination is advantageous in people at risk. (5) All mass vaccination programmes must include systematic monitoring of adverse effects. |
|---|
